US FTC suspends challenge to block Amgen’s $27.8 billion deal for Horizon Therapeutics
(Reuters) -The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen’s $27.8 billion purchase of Horizon Therapeutics, allowing the FTC to consider whether the agency should settle the case, a filing late on Friday showed. The pause is effective until Sept. 18. Amgen said the company was aware of the move and is…
